secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001193125-25-316904
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM
------------------------------------------------------------------------

- CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).
- Indicated for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults.
- European Commission final decision expected in Q1 2026.
- MYQORZO is a cardiac myosin inhibitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/0001193125-25-316904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/cytk-20251212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-316904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer